Cargando…

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hao, Li, Yingmei, Zhang, Peng, Xing, Haizhou, Zhao, Song, Song, Yongping, Wan, Dingming, Yu, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727882/
https://www.ncbi.nlm.nih.gov/pubmed/36476317
http://dx.doi.org/10.1186/s40364-022-00436-7
_version_ 1784845122352971776
author Sun, Hao
Li, Yingmei
Zhang, Peng
Xing, Haizhou
Zhao, Song
Song, Yongping
Wan, Dingming
Yu, Jifeng
author_facet Sun, Hao
Li, Yingmei
Zhang, Peng
Xing, Haizhou
Zhao, Song
Song, Yongping
Wan, Dingming
Yu, Jifeng
author_sort Sun, Hao
collection PubMed
description Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response in the highly sophisticated process of innate immunity signaling with the recent research advances involving the small molecule activation of TLR 7 and 8. The wide range of expression and clinical significance of TLR7/TLR8 in different kinds of cancers have been extensively explored. TLR7/TLR8 can be used as novel diagnostic biomarkers, progression and prognostic indicators, and immunotherapeutic targets for various tumors. Although the mechanism of action of TLR7/8 in cancer immunotherapy is still incomplete, TLRs on T cells are involved in the regulation of T cell function and serve as co-stimulatory molecules and activate T cell immunity. TLR agonists can activate T cell-mediated antitumor responses with both innate and adaptive immune responses to improve tumor therapy. Recently, novel drugs of TLR7 or TLR8 agonists with different scaffolds have been developed. These agonists lead to the induction of certain cytokines and chemokines that can be applied to the treatment of some diseases and can be used as good adjutants for vaccines. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed. In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B.
format Online
Article
Text
id pubmed-9727882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97278822022-12-08 Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives Sun, Hao Li, Yingmei Zhang, Peng Xing, Haizhou Zhao, Song Song, Yongping Wan, Dingming Yu, Jifeng Biomark Res Review Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response in the highly sophisticated process of innate immunity signaling with the recent research advances involving the small molecule activation of TLR 7 and 8. The wide range of expression and clinical significance of TLR7/TLR8 in different kinds of cancers have been extensively explored. TLR7/TLR8 can be used as novel diagnostic biomarkers, progression and prognostic indicators, and immunotherapeutic targets for various tumors. Although the mechanism of action of TLR7/8 in cancer immunotherapy is still incomplete, TLRs on T cells are involved in the regulation of T cell function and serve as co-stimulatory molecules and activate T cell immunity. TLR agonists can activate T cell-mediated antitumor responses with both innate and adaptive immune responses to improve tumor therapy. Recently, novel drugs of TLR7 or TLR8 agonists with different scaffolds have been developed. These agonists lead to the induction of certain cytokines and chemokines that can be applied to the treatment of some diseases and can be used as good adjutants for vaccines. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed. In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B. BioMed Central 2022-12-07 /pmc/articles/PMC9727882/ /pubmed/36476317 http://dx.doi.org/10.1186/s40364-022-00436-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Sun, Hao
Li, Yingmei
Zhang, Peng
Xing, Haizhou
Zhao, Song
Song, Yongping
Wan, Dingming
Yu, Jifeng
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title_full Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title_fullStr Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title_full_unstemmed Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title_short Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
title_sort targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727882/
https://www.ncbi.nlm.nih.gov/pubmed/36476317
http://dx.doi.org/10.1186/s40364-022-00436-7
work_keys_str_mv AT sunhao targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT liyingmei targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT zhangpeng targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT xinghaizhou targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT zhaosong targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT songyongping targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT wandingming targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives
AT yujifeng targetingtolllikereceptor78forimmunotherapyrecentadvancesandprospectives